Total Payments
$49,879
2024 Payments
$6,353
Companies
52
Transactions
292
Medicare Patients
12,743
Medicare Billing
$4.0M
Payment Breakdown by Category
Consulting$30,056 (60.3%)
Other$10,711 (21.5%)
Food & Beverage$6,298 (12.6%)
Travel$1,576 (3.2%)
Education$1,238 (2.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $30,056 | 20 | 60.3% |
| Honoraria | $8,226 | 7 | 16.5% |
| Food and Beverage | $6,298 | 221 | 12.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,485 | 2 | 5.0% |
| Travel and Lodging | $1,576 | 10 | 3.2% |
| Education | $1,238 | 32 | 2.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $9,455 | 17 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $8,255 | 18 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $5,528 | 15 | $0 (2024) |
| Blueprint Medicines Corporation | $4,169 | 4 | $0 (2022) |
| G1 Therapeutics, Inc. | $3,000 | 2 | $0 (2022) |
| BeiGene USA, Inc. | $2,177 | 5 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $2,115 | 55 | $0 (2023) |
| Celgene Corporation | $1,557 | 2 | $0 (2022) |
| Janssen Biotech, Inc. | $1,486 | 11 | $0 (2021) |
| Exelixis Inc. | $1,338 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,353 | 36 | AstraZeneca Pharmaceuticals LP ($3,628) |
| 2023 | $2,232 | 42 | Amgen Inc. ($745.96) |
| 2022 | $7,231 | 26 | Blueprint Medicines Corporation ($4,169) |
| 2021 | $6,613 | 38 | E.R. Squibb & Sons, L.L.C. ($1,543) |
| 2020 | $8,576 | 22 | AstraZeneca Pharmaceuticals LP ($1,665) |
| 2019 | $16,342 | 37 | Novartis Pharmaceuticals Corporation ($9,282) |
| 2018 | $1,385 | 35 | Janssen Biotech, Inc. ($306.98) |
| 2017 | $1,147 | 56 | Biocompatibles, Inc. ($212.87) |
All Payment Transactions
292 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $23.39 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $23.01 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Incyte Corporation | MONJUVI (Drug), PEMAZYRE | Food and Beverage | Cash or cash equivalent | $22.43 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Legend Biotech USA Inc. | — | Food and Beverage | In-kind items and services | $16.55 | General |
| 12/05/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $28.71 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.16 | General |
| 11/25/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $17.49 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $17.86 | General |
| Category: Hematology/Oncology | ||||||
| 11/15/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $275.00 | General |
| Category: Oncology | ||||||
| 11/04/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $22.95 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/29/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $26.88 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $33.58 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,497.50 | General |
| 10/07/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $22.74 | General |
| Category: Oncology | ||||||
| 10/02/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $23.70 | General |
| Category: Oncology | ||||||
| 09/14/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $18.96 | General |
| Category: ONCOLOGY | ||||||
| 09/09/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $14.12 | General |
| Category: ONCOLOGY | ||||||
| 09/02/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $24.57 | General |
| 08/01/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 07/10/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $18.40 | General |
| Category: ONCOLOGY | ||||||
| 06/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Vitrakvi (Drug) | Consulting Fee | Cash or cash equivalent | $1,140.00 | General |
| Category: Oncology | ||||||
| 06/12/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Education | In-kind items and services | $83.99 | General |
| Category: ONC | ||||||
| 05/21/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $28.84 | General |
| 05/13/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| Category: ONCOLOGY | ||||||
| 05/08/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $22.83 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 52 | 2,898 | 52,481 | $2.0M | $343,975 |
| 2022 | 51 | 3,086 | 101,111 | $4.6M | $1.1M |
| 2021 | 58 | 3,890 | 106,091 | $5.2M | $1.3M |
| 2020 | 50 | 2,869 | 110,174 | $5.2M | $1.3M |
Total Patients
12,743
Total Services
369,857
Medicare Billing
$4.0M
Procedure Codes
211
All Medicare Procedures & Services
211 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 35 | 3,960 | $279,180 | $73,142 | 26.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 355 | 579 | $118,795 | $34,961 | 29.4% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 19 | 2,000 | $155,400 | $32,428 | 20.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 171 | 365 | $111,325 | $32,375 | 29.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 65 | 340 | $233,240 | $31,370 | 13.4% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 17 | 3,610 | $108,300 | $22,318 | 20.6% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 19 | 3,560 | $195,800 | $19,995 | 10.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 59 | 63 | $36,855 | $8,374 | 22.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 350 | 1,019 | $35,665 | $7,736 | 21.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 72 | 152 | $46,208 | $6,764 | 14.6% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 17 | 15,810 | $94,860 | $6,407 | 6.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 44 | 44 | $20,900 | $4,993 | 23.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 31 | 37 | $15,170 | $4,816 | 31.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 27 | 51 | $15,300 | $4,581 | 29.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 27 | 27 | $15,930 | $4,296 | 27.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 182 | 407 | $25,234 | $4,212 | 16.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 52 | 68 | $14,280 | $4,141 | 29.0% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 60 | 199 | $30,248 | $4,115 | 13.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 25 | 82 | $27,388 | $3,819 | 13.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 96 | 378 | $35,154 | $3,783 | 10.8% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 140 | 204 | $11,832 | $2,714 | 22.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 34 | 34 | $10,540 | $2,592 | 24.6% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 45 | 232 | $24,360 | $2,571 | 10.6% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 19 | 19 | $9,937 | $2,350 | 23.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 56 | 59 | $7,375 | $2,154 | 29.2% |
About Dr. Evan Lang, MD
Dr. Evan Lang, MD is a Hematology & Oncology healthcare provider based in Hamilton, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2005. The National Provider Identifier (NPI) number assigned to this provider is 1639163033.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Evan Lang, MD has received a total of $49,879 in payments from pharmaceutical and medical device companies, with $6,353 received in 2024. These payments were reported across 292 transactions from 52 companies. The most common payment nature is "Consulting Fee" ($30,056).
As a Medicare-enrolled provider, Lang has provided services to 12,743 Medicare beneficiaries, totaling 369,857 services with total Medicare billing of $4.0M. Data is available for 4 years (2020–2023), covering 211 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Hematology & Oncology
- Location Hamilton, OH
- Active Since 08/31/2005
- Last Updated 04/19/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1639163033
Products in Payments
- TASIGNA (Drug) $9,282
- Xofigo (Drug) $6,087
- AYVAKIT (Drug) $4,169
- BRUKINSA (Drug) $3,152
- COSELA (Drug) $3,000
- Vitrakvi (Drug) $2,150
- TAGRISSO (Drug) $1,665
- IMBRUVICA (Drug) $1,645
- Pomalyst (Drug) $1,557
- Cabometyx (Drug) $1,338
- ZEPZELCA (Drug) $1,283
- BRAFTOVI (Drug) $1,274
- IMFINZI (Biological) $1,066
- LUMAKRAS (Drug) $748.78
- OJJAARA (Drug) $668.40
- PYRUKYND (Drug) $637.50
- Imbruvica (Drug) $476.23
- OPDIVO (Biological) $409.50
- KEYTRUDA (Biological) $372.85
- THERASPHERE - BIO (Device) $212.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.